News By Tag
* Life Sciences
* Phase I
* Phase Ii
* More Tags...
News By Location
Insight Pharma Reports RNAi Therapeutics Report
RNAi Therapeutics: Second-Generation Candidates Build Momentum
Many established pharma companies have entered into major deals with some of these RNAi therapeutics companies. Also covered are companies focus on development of microRNA-based therapeutics and diagnostics. These have attracted the interest of the investment community and the pharmaceutical industry. This report discusses the outlook for the therapeutic RNAi/miRNA industry sector, including strategic issues such as technological prematurity and the development of enabling technologies, the role of Big Pharma investment, the impact of patent litigation and cross-licensing in shaping the RNAi/miRNA sector, and a scenario for the development of drugs in the therapeutic RNAi/miRNA sector.
Key topics covered include:
Following an overview of the discovery and evolution of the RNAi and miRNA field, RNAi Therapeutics:
For more information and to purchase this report, go to:
About Insight Pharma Reports (http://www.InsightPharmaReports.com)
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com
# # #
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.